Introduction: The rapidly expanding era of “omics” research is highly
dependent on the availability of quality-proven biological material,
especially for rare conditions such as pediatric malignancies.
Professional biobanks provide such material, focusing on standardized
collection and handling procedures, distinctive quality measurements,
traceability of storage conditions, and accessibility. For pediatric
malignancies traditional tumor biobanking is challenging due to the
rareness and limited amount of tissue and blood samples. The higher
molecular heterogeneity, lower mutation rates, and unique genomic
landscapes, however, renders biobanking of this tissue even more
crucial. Aim: The aim of this study was to test and establish methods
for a prospective and centralized biobank for infants, children and
adolescents up to 18 years of age diagnosed with cancer in Norway.
Methods: Obtain judicial and ethical approvals and administration
through a consortium, steering committee and advisory board. Develop
pipelines including SOPs for all aspects in the biobank process,
including collection, processing and storing of samples and data, as
well of quality controlling, safeguarding, distributing and transport.
Results: The childhood cancer biobanking started at Oslo University
Hospital (OUH) in March 2017 and was from 2019 run as a national
Norwegian Childhood Cancer Biobank (NCCB). Informed consent and
biological samples are collected regionally and stored centrally.
Approximately 12000 samples from 510 patients and have been included by
01.01.2021, representing a 96% consent and participation rate among our
newly diagnosed patients. Conclusion: A well functioning nationwide
collection and centralized biobank with standardized procedures and
national storage for pediatric malignancies has been established with a
high acceptance among families.